GHRP-6 20mg/vial 1 Vial by Bluepeps

Usage

1. Reconstitute the 20 mg vial by adding 2 mL of bacteriostatic water along the vial wall to produce a 10 mg/mL solution; avoid vigorous agitation.
2. Refrigerate the reconstituted vial at 2–8 °C immediately and label with the date of reconstitution.
3. Draw 0.01 mL per 100 mcg dose into a U-100 insulin syringe — confirm the correct graduation before injection.
4. Administer subcutaneously in a fasted state (minimum 2 hours post-meal, 30 minutes pre-meal) to prevent elevated glucose from suppressing the GH pulse via somatostatin.
5. Rotate injection sites systematically across the abdominal subcutaneous layer to minimise local tissue stress during multi-week bridge protocols.
6. Discard any remaining reconstituted solution after 28 days; do not use vials showing particulates or discolouration.

Warnings

Frequently asked questions

Can GHRP-6 be used during PCT without suppressing natural testosterone recovery?

Yes. GHRP-6 acts exclusively on the GHS-R1a receptor in the pituitary, stimulating GH release without any interaction with the hypothalamic-pituitary-gonadal axis. It does not suppress LH, FSH, or endogenous testosterone production, which makes it compatible with standard PCT protocols using SERMs such as tamoxifen or clomiphene.

Which peptides are considered appropriate for an inter-cycle bridge phase?

GHRP-6 is frequently selected for bridge use because it maintains anabolic signalling — via pulsatile GH and downstream IGF-1 — without introducing hormonal suppression. CJC-1295 (without DAC) is often co-administered to amplify pulse amplitude. The combination preserves muscle and connective tissue during the off-cycle window, a period when catabolism risk is highest.

How does GHRP-6 help protect joints after an anabolic cycle ends?

GH pulses triggered by GHRP-6 stimulate synovial fibroblasts to produce collagen II and proteoglycans — the structural components of joint cartilage. Post-cycle, when androgen-driven collagen synthesis falls, this GH-mediated pathway provides a compensatory mechanism. Research protocols report subjective joint comfort improvements within three to four weeks of consistent 100–200 mcg dosing.

How do you dose and reconstitute the Bluepeps GHRP-6 20 mg vial for a bridge protocol?

Add 2 mL of bacteriostatic water to yield a 10 mg/mL (10,000 mcg/mL) stock solution. A standard 100 mcg research dose equals 0.01 mL drawn into a U-100 insulin syringe. For a bridge protocol, two to three injections daily across eight to twelve weeks are typical. Refrigerate the reconstituted vial immediately and use within 28 days.

What is the storage advantage of the 20 mg/vial format for a multi-week PCT or bridge?

At 20 mg per vial — the highest concentration in this GHRP-6 product group — a single vial provides approximately 200 doses at 100 mcg each, sufficient to cover a ten-week bridge at twice-daily dosing without restocking. Lyophilised and sealed under inert atmosphere, the unopened vial remains stable for 24 months at 2–8 °C. (2) angle_used

Manufacturer

Bluepeps has built its GHRP-6 20 mg vial around a specialisation model focused on single-ingredient peptide formats where concentration precision is paramount: the declared 20 mg active content per vial is confirmed lot-by-lot through reversed-phase HPLC sequence verification, and residual endotoxin load is quantified via Limulus Amebocyte Lysate assay against defined release thresholds. Vials are lyophilised under ISO-classified cleanroom conditions and sealed under inert atmosphere to protect peptide integrity throughout the cold-chain. A lot-specific certificate of analysis accompanies each batch, giving researchers full traceability from production to delivery.